Liege

• Efficacy and Safety of Icotrokinra in Adult and Adolescent Participants with Moderately to Severely Active Ulcerative Colitis Recruiting
  2025-521381-10-00 5 2025-12-03 Moderately to Severely Active Ulcerative Colitis
• A study to find out how EMPAgliflozin is tolerated and if it helps children and adolescents with chronic KIDNEY disease (EMPA-KIDNEY Kids) Recruiting
  2024-512577-27-00 5 2025-12-02 Chronic kidney disease in paediatric patients
• A phase 3b study of depemokimab on airway structure and function in patients with type 2 asthma utilizing quantitative high-resolution CT an … Recruiting
  2024-519976-19-00 5 2025-11-26 Asthma with type 2 inflammation characterized by an eosinophilic pheno
• Pasritamig vs Placebo in late line Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
  2025-520927-26-00 5 2025-11-24 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa … Recruiting
  2024-511392-15-00 5 2025-11-20 HR+/HER2- advanced breast cancer
• A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors Recruiting
  2025-520623-24-00 7 2025-11-19 MTAP-deleted Solid Tumors
• A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting
  2024-520190-12-00 5 2025-11-10 Breast Cancer: triple negative breast cancer (TNBC) and hormone recept
• A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan … Recruiting
  2025-520566-22-00 5 2025-11-10 Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Ca
• TRITON-CM: A Study to Evaluate Nucresiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Recruiting
  2024-519917-72-00 5 2025-10-29 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• A Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib (BMS-986165) in Adolescent Participants with Moder … Recruiting
  2023-506296-97-00 5 2025-10-28 Moderate to Severe Plaque Psoriasis
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i … Recruiting
  2024-518365-10-00 5 2025-10-28 Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
• A first-in-human, randomized, double-blind, placebo-controlled, three-part study assessing the safety, tolerability, pharmacokinetics and ph … Recruiting
  2025-521556-35-00 1 2025-10-28 Narcolepsy
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and … Recruiting
  2024-517140-65-00 9 2025-10-23 Multiple Myeloma (MM).
• A Study to Assess the Adverse Events, Effectiveness, and How the Drug Moves through the Body of Intravenous and Subcutaneous Injections of R … Recruiting
  2024-514695-41-00 5 2025-10-17 Ulcerative Colitis
• A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hid … Recruiting
  2025-520564-17-00 5 2025-10-16 Hidradenitis suppurativa (HS)
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting
  2024-514822-21-00 5 2025-10-02 Platinum-resistant Ovarian Cancer
• A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-to-Severe Asthma Recruiting
  2024-517866-40-00 4 2025-09-29 Moderate-to-severe Asthma
• A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutec … Recruiting
  2024-518015-19-00 4 2025-09-24 Colorectal Cancer
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight: … Recruiting
  2024-520210-21-00 5 2025-09-19 Crohn’s Disease
• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung … Recruiting
  2024-517780-24-00 5 2025-09-18 Lung Cancer
• A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination with Osimertinib as Firs … Recruiting
  2024-518586-10-00 10 2025-09-18 Non-Squamous Non-Small Cell Lung Cancer

Showing 145–168 of 639 trials